Overview

Nasal High Flow therapy is being widely adopted in neonatal and pediatric practice. The literature supports the early and integrated use of Nasal High Flow therapy to optimize the patient journey.

The impact of a new therapy at the Rosie

Optiflow™ Junior in Practice

The Rosie Hospital is part of Cambridge University Hospitals NHS Foundation Trust, one of the largest and best-known trusts in the United Kingdom. The unit is one of the biggest in the United Kingdom with a 58-cot capacity and is the referral center for the East of England region. Watch this video series to learn about their journey to successfully implementing Nasal High Flow therapy into their Neonatal Intensive Care Unit.

Watch the video series

Health Economic Benefits are Emerging

If a patient is able to avoid escalation of therapy^1,2 and has a shorter length of stay³ in an intensive care setting, this may result in overall cost savings to the hospital¹.

Find out more

Mayfield S, Bogossian F, O'Malley L, et al. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: Pilot study. J Paediatr Child Health 2014;50(5):373-8
Wing R, James C, Maranda L, et al. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. Pediatr Emerg Care 2012;28(11):1117-23
McKiernan C, Chua L, Visintainer P, et al. High flow nasal cannulae therapy in infants with bronchiolitis. J Pediatr 2010;156(4):634-8

Overview

Optiflow™ Junior in Practice

Health Economic Benefits are Emerging

View references